BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 31118465)

  • 21. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
    Cho JH; Shim JH; Yoon SE; Kim HJ; Kim SH; Ko YH; Lee ST; Kim K; Kim WS; Kim SJ
    Korean J Intern Med; 2021 May; 36(3):668-678. PubMed ID: 32791817
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A prognostic index predicting survival in transformed Waldenström macroglobulinemia.
    Durot E; Kanagaratnam L; Zanwar S; Kastritis E; D'Sa S; Garcia-Sanz R; Tomowiak C; Hivert B; Toussaint E; Protin C; Abeykoon JP; Guerrero-Garcia T; Itchaki G; Vos JM; Michallet AS; Godet S; Dupuis J; Leprêtre S; Bomsztyk J; Morel P; Leblond V; Treon SP; Dimopoulos MA; Kapoor P; Delmer A; Castillo JJ
    Haematologica; 2021 Nov; 106(11):2940-2946. PubMed ID: 33179472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
    Anderson KC; Alsina M; Bensinger W; Biermann JS; Cohen AD; Devine S; Djulbegovic B; Faber EA; Gasparetto C; Hernandez-Ilizaliturri F; Huff CA; Kassim A; Krishnan AY; Medeiros BC; Meredith R; Raje N; Schriber J; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Tricot G; Weber DM; Yahalom J; Yunus F; Kumar R; Shead DA;
    J Natl Compr Canc Netw; 2012 Oct; 10(10):1211-9. PubMed ID: 23054875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Waldenström's macroglobulinemia.
    Dimopoulos MA; Anagnostopoulos A
    Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands.
    Klodzinska S; Vos JM; Kersten MJ; Wijermans P; Minnema MC
    Neth J Med; 2013 Mar; 71(2):90-6. PubMed ID: 23462060
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification.
    Paiva B; Montes MC; García-Sanz R; Ocio EM; Alonso J; de Las Heras N; Escalante F; Cuello R; de Coca AG; Galende J; Hernández J; Sierra M; Martin A; Pardal E; Bárez A; Alonso J; Suarez L; González-López TJ; Perez JJ; Orfao A; Vidríales MB; San Miguel JF
    Leukemia; 2014 Jan; 28(1):166-73. PubMed ID: 23604227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
    Buske C; Sadullah S; Kastritis E; Tedeschi A; García-Sanz R; Bolkun L; Leleu X; Willenbacher W; Hájek R; Minnema MC; Cheng M; Bilotti E; Graef T; Dimopoulos MA;
    Lancet Haematol; 2018 Jul; 5(7):e299-e309. PubMed ID: 29958569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
    Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
    Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group.
    Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E;
    J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
    Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
    Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
    Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Waldenström's macroglobulinemia. Current developments in diagnostics and therapy].
    Grunenberg A; Buske C
    Internist (Berl); 2016 Mar; 57(3):238-44. PubMed ID: 26830425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis and treatment of Waldenström's macroglobulinemia.
    Louw VJ; Webb MJ
    Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia.
    Herth I; Hensel M; Rieger M; Horstmann K; Hiddemann W; Dreyling M; Koniczek S; Witzens-Harig M; Ho AD
    Leuk Lymphoma; 2015 Jan; 56(1):97-102. PubMed ID: 24724778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of Waldenström's macroglobulinemia with rituximab.
    Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
    J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
    Lévy V; Morel P; Porcher R; Chevret S; Wattel E; Leblond V
    Haematologica; 2005 Feb; 90(2):279-81. PubMed ID: 15710594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Waldenström macroglobulinemia. Experience in 31 patients].
    Cardemil D; León P; Peña C; Valladares X; Cabrera ME
    Rev Med Chil; 2019 Mar; 147(3):275-280. PubMed ID: 31344163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.